These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 11069790)

  • 21. Cost-effectiveness of 3 months of weekly rifapentine and isoniazid compared with other standard treatment regimens for latent tuberculosis infection: a decision analysis study.
    Doan TN; Fox GJ; Meehan MT; Scott N; Ragonnet R; Viney K; Trauer JM; McBryde ES
    J Antimicrob Chemother; 2019 Jan; 74(1):218-227. PubMed ID: 30295760
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Improved adherence and less toxicity with rifampin vs isoniazid for treatment of latent tuberculosis: a retrospective study.
    Page KR; Sifakis F; Montes de Oca R; Cronin WA; Doherty MC; Federline L; Bur S; Walsh T; Karney W; Milman J; Baruch N; Adelakun A; Dorman SE
    Arch Intern Med; 2006 Sep; 166(17):1863-70. PubMed ID: 17000943
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cost-effectiveness of a 12-dose regimen for treating latent tuberculous infection in the United States.
    Shepardson D; Marks SM; Chesson H; Kerrigan A; Holland DP; Scott N; Tian X; Borisov AS; Shang N; Heilig CM; Sterling TR; Villarino ME; Mac Kenzie WR
    Int J Tuberc Lung Dis; 2013 Dec; 17(12):1531-7. PubMed ID: 24200264
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Health System Costs of Treating Latent Tuberculosis Infection With Four Months of Rifampin Versus Nine Months of Isoniazid in Different Settings.
    Bastos ML; Campbell JR; Oxlade O; Adjobimey M; Trajman A; Ruslami R; Kim HJ; Baah JO; Toelle BG; Long R; Hoeppner V; Elwood K; Al-Jahdali H; Apriani L; Benedetti A; Schwartzman K; Menzies D
    Ann Intern Med; 2020 Aug; 173(3):169-178. PubMed ID: 32539440
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A retrospective evaluation of completion rates, total cost, and adverse effects for treatment of latent tuberculosis infection in a public health clinic in central massachusetts.
    Young H; Wessolossky M; Ellis J; Kaminski M; Daly JS
    Clin Infect Dis; 2009 Aug; 49(3):424-7. PubMed ID: 19548835
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Completing tuberculosis prophylaxis in jail: targeting treatment and comparison of rifampin/pyrazinamide with isoniazid regimens.
    Lincoln T; Brannan GL; Lynch V; Conklin TJ; Clancey T; Rose DN; Tuthill RJ
    Int J Tuberc Lung Dis; 2004 Mar; 8(3):306-11. PubMed ID: 15139468
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cost-effectiveness of rifampin for 4 months and isoniazid for 9 months in the treatment of tuberculosis infection.
    Pina JM; Clotet L; Ferrer A; Sala MR; Garrido P; Salleras L; Domínguez A
    Eur J Clin Microbiol Infect Dis; 2013 May; 32(5):647-55. PubMed ID: 23238684
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Enhancement of treatment completion for latent tuberculosis infection with 4 months of rifampin.
    Lardizabal A; Passannante M; Kojakali F; Hayden C; Reichman LB
    Chest; 2006 Dec; 130(6):1712-7. PubMed ID: 17166986
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cost-effectiveness of Preventive Therapy for Tuberculosis With Isoniazid and Rifapentine Versus Isoniazid Alone in High-Burden Settings.
    Johnson KT; Churchyard GJ; Sohn H; Dowdy DW
    Clin Infect Dis; 2018 Sep; 67(7):1072-1078. PubMed ID: 29617965
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Effectiveness and problems of PZA-containing 6-month regimen for the treatment of new pulmonary tuberculosis patients].
    Wada M
    Kekkaku; 2001 Jan; 76(1):33-43. PubMed ID: 11211781
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Rifapentine and isoniazid in the continuation phase of treating pulmonary tuberculosis. Initial report.
    Tam CM; Chan SL; Lam CW; Leung CC; Kam KM; Morris JS; Mitchison DA
    Am J Respir Crit Care Med; 1998 Jun; 157(6 Pt 1):1726-33. PubMed ID: 9620898
    [TBL] [Abstract][Full Text] [Related]  

  • 32. SIRCLE: a randomised controlled cost comparison of self-administered short-course isoniazid and rifapentine for cost-effective latent tuberculosis eradication.
    Denholm JT; McBryde ES; Eisen D; Street A; Matchett E; Chen C; Shultz TR; Biggs B; Leder K
    Intern Med J; 2017 Dec; 47(12):1433-1436. PubMed ID: 29224209
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Six-month isoniazid-rifampin treatment for pulmonary tuberculosis in children.
    Reis FJ; Bedran MB; Moura JA; Assis I; Rodrigues ME
    Am Rev Respir Dis; 1990 Nov; 142(5):996-9. PubMed ID: 2240853
    [TBL] [Abstract][Full Text] [Related]  

  • 34. New regimens to prevent tuberculosis in adults with HIV infection.
    Martinson NA; Barnes GL; Moulton LH; Msandiwa R; Hausler H; Ram M; McIntyre JA; Gray GE; Chaisson RE
    N Engl J Med; 2011 Jul; 365(1):11-20. PubMed ID: 21732833
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Short-course chemotherapy for tuberculosis with mainly twice-weekly isoniazid and rifampin. Community physicians' seven-year experience with mainly outpatients.
    Dutt AK; Moers D; Stead WW
    Am J Med; 1984 Aug; 77(2):233-42. PubMed ID: 6431810
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Clinical trial of six-month and four-month regimens of chemotherapy in the treatment of pulmonary tuberculosis.
    Am Rev Respir Dis; 1979 Apr; 119(4):579-85. PubMed ID: 375787
    [TBL] [Abstract][Full Text] [Related]  

  • 37. U.S. Public Health Service Cooperative trial of three rifampin-isoniazid regimens in treatment of pulmonary tuberculosis.
    Long MW; Snider DE; Farer LS
    Am Rev Respir Dis; 1979 Jun; 119(6):879-94. PubMed ID: 110184
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Comparison of daily and twice-weekly regimens to treat pulmonary tuberculosis.
    Castelo A; Jardim JR; Goihman S; Kalckman AS; Dalboni MA; da Silva EA; Haynes RB
    Lancet; 1989 Nov; 2(8673):1173-6. PubMed ID: 2572899
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Six-months isoniazid-rifampin therapy for pulmonary tuberculosis. Report of a United States Public Health Service Cooperative Trial.
    Snider DE; Long MW; Cross FS; Farer LS
    Am Rev Respir Dis; 1984 Apr; 129(4):573-9. PubMed ID: 6370060
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Safety and Side Effects of Rifampin versus Isoniazid in Children.
    Diallo T; Adjobimey M; Ruslami R; Trajman A; Sow O; Obeng Baah J; Marks GB; Long R; Elwood K; Zielinski D; Gninafon M; Wulandari DA; Apriani L; Valiquette C; Fregonese F; Hornby K; Li PZ; Hill PC; Schwartzman K; Benedetti A; Menzies D
    N Engl J Med; 2018 Aug; 379(5):454-463. PubMed ID: 30067928
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.